#Biocon Foundation, the CSR arm of Biocon Group, in collaboration with the Indian Institute of Science (IISc), proudly hosted the 5th #OralCancerTaskForce (OCTF) Conference on July 26-27, 2024. This two-day event at the IISc campus, marking World Head & Neck Cancer Day, centered on 'Artificial Intelligence in Oral Cancer.' The conference united clinicians and scientists to discuss breakthroughs in oral cancer screening and early detection. For nearly a decade, Biocon Foundation's Oral Cancer Control Program (OCCP) has been dedicated to early detection in underserved communities, screening over 85,000 individuals across India, with 13% identified as positive for Oral Potentially Malignant Disorders (OPMDs). Biocon Foundation has partnered with IISc on the AI-Center of Excellence in Oral Cancer Projects, a multicentric study with 28 consortium partners. As the lead expert for phase 1, we're developing Aarogya Aarohan, an AI-assisted mobile phone-based white light imaging system to classify oral lesions as high-risk or low-risk for oral cancer. This project underscores the transformative role of #AI in #healthcare. Read more: https://bit.ly/3yBVgea
About us
Biocon: Enhancing Global Healthcare Biocon Limited, publicly listed in 2004, is India's largest and fully-integrated, innovation-led biopharmaceutical company. It is an emerging global biopharmaceutical enterprise serving customers in over 120 countries. Driven by a vision to enhance global healthcare through innovative and affordable biopharmaceuticals, we have enabled access to advanced therapies for diseases that are chronic, where medical needs are largely unmet and treatment costs are high. The early anticipation of the increasing dominance of biologics in global development pipelines helped us to be ahead of the curve in crafting a differentiated product portfolio based on fermentation and recombinant technologies, which straddles fermentation-derived small molecules and biologics, both novel as well as biosimilars. The significant brand equity that we have built worldwide for our small molecule APIs across statins, immunosuppresants and other specialty products has made us a leading global supplier of these products. We have also built one of the largest and most diverse biosimilar pipelines, spanning insulins, monoclonal antibodies and other recombinant proteins that address critical chronic diseases such as diabetes, cancer and autoimmune disorders. Ranked among the Top 3 biosimilar players globally for rh-insulin and insulin glargine in volume terms, we are the first Indian company to launch a biosimilar in Japan with Insulin Glargine, which also has been approved for sale in EU and Australia. Our insulin products have made a difference to the lives of millions of people with diabetes across the globe. We now aim to provide our insulin products to ‘one in five’ people with diabetes in need of insulin-based therapy anywhere in the world within the next 10 years. We are also making a huge impact in the area of cancer care. Our biosimilar Trastuzumab, which was the first to be approved anywhere in the world and launched in India in 2014, has helped treat several thousand HER2-positive metastatic breast cancer patients. We are also the first company from India to get its biosimilar approved by the USFDA; Ogivri™, co-developed by Biocon and Mylan, is the first biosimilar Trastuzumab to be approved in the US. In addition to Trastuzumab, several of our biosimilar assets are on track for anticipated regulatory approvals in developed markets. We are also developing a pipeline of patented biologics to address global unmet medical needs. We have successfully launched a couple of novel biologics in India: Nimotuzumab for the treatment of head and neck cancer and Itolizumab to tackle psoriasis. Besides these, we have a basket of novel assets are under various stages of clinical development, including a high potential oral insulin. Through our subsidiary, Syngene, we offer a suite of integrated, end-to-end discovery and development services for novel molecular entities (NMEs) to the global life sciences sector. Ranked by the prestigious Science magazine among the Top 10 Best employers in the biotech industry, Biocon is passionately pursuing a mission to rationalize healthcare spends, enhance access to life-saving therapies and make a significant impact to global healthcare through ‘blockbuster’ drugs with the potential to benefit a billion patients.
- Website
-
http://www.biocon.com
External link for Biocon
- Industry
- Biotechnology Research
- Company size
- 5,001-10,000 employees
- Headquarters
- Bangalore, Karnataka
- Type
- Public Company
Locations
-
Primary
Hosur Road, Electronics City
Bangalore, Karnataka 560100, IN
Employees at Biocon
Updates
-
#WelcomeToBiocon: Always excited to welcome new #Bioconites to the team! Congratulations, and we look forward to you contributing to our purpose of providing everyone, everywhere, affordable access to medicines. #Biocon
-
Celebrating Excellence ! We had an amazing time at our 3rd Group COE Annual Awards Ceremony 2024 on July 5th at Tyler Jacks Auditorium, Biocon Park. It was a fantastic event organized by the Group COE team led by Parth S. and his team Piyush Soni Ritwick Tandon Anil Kumar Chilagani Rohit Kurup & Umang Kaushik where we recognized and celebrated our employees' incredible achievements. Awards were given out in categories of Lean Six Sigma Black Belt, Green Belt and Yellow Belt projects, Best Kaizens generated, 5S implementation and Biocon’s very own John Shaw Excellence Model. Kiran Mazumdar Shaw, our Executive Chairperson, was the Guest of Honor and gave an inspiring speech. We had 400 employees join us in person and over 1300 virtually! Our leadership team from Biocon, Biocon Biologics , and Syngene International Limited were all there to support and congratulate the winners. We also had a special episode of the Utkarsh Leadership Talk Series powered by Group COE with Kiran Mazumdar Shaw and Soumitra Bhattacharya CEO and Executive Director, IFQM (Indian Foundation for Quality Management) sharing their insights on business excellence. Congrats to all the winners and participants! Your hard work and dedication are truly inspiring. 🌟 #BioconBiologics #AnnualAwards #Excellence #Teamwork #Celebration #biocongroup #syngene Kiran Mazumdar Shaw Siddharth Mittal Shreehas Tambe Naveen Narayanan Maninder Kapoor Puri Rhonda Duffy Sandeep Athalye Alok Mehrotra Kenneth Barr, Ph.D. Vishal Nayyar Anuj Goel Amit Kaptain Syngene International Limited Biocon
-
+4
-
Biocon reposted this
Celebrating Excellence ! We had an amazing time at our 3rd Group COE Annual Awards Ceremony 2024 on July 5th at Tyler Jacks Auditorium, Biocon Park. It was a fantastic event organized by the Group COE team led by Parth S. and his team Piyush Soni Ritwick Tandon Anil Kumar Chilagani Rohit Kurup & Umang Kaushik where we recognized and celebrated our employees' incredible achievements. Awards were given out in categories of Lean Six Sigma Black Belt, Green Belt and Yellow Belt projects, Best Kaizens generated, 5S implementation and Biocon’s very own John Shaw Excellence Model. Kiran Mazumdar Shaw, our Executive Chairperson, was the Guest of Honor and gave an inspiring speech. We had 400 employees join us in person and over 1300 virtually! Our leadership team from Biocon, Biocon Biologics , and Syngene International Limited were all there to support and congratulate the winners. We also had a special episode of the Utkarsh Leadership Talk Series powered by Group COE with Kiran Mazumdar Shaw and Soumitra Bhattacharya CEO and Executive Director, IFQM (Indian Foundation for Quality Management) sharing their insights on business excellence. Congrats to all the winners and participants! Your hard work and dedication are truly inspiring. 🌟 #BioconBiologics #AnnualAwards #Excellence #Teamwork #Celebration #biocongroup #syngene Kiran Mazumdar Shaw Siddharth Mittal Shreehas Tambe Naveen Narayanan Maninder Kapoor Puri Rhonda Duffy Sandeep Athalye Alok Mehrotra Kenneth Barr, Ph.D. Vishal Nayyar Anuj Goel Amit Kaptain Syngene International Limited Biocon
-
+4
-
“The Union Budget for FY25 builds further on the government’s pre-election, Interim Budget and has positive indicators on how the government is looking at India’s economic growth and development. The FM’s emphasis on job creation through skilling is a key underlying theme. Internships at large companies with Government and CSR backed stipends is the right approach to employability and jobs for the future. The budget has also focused on the start up ecosystem and provided a fillip through the abolition of the ‘angel tax’ which is aimed at spurring investments in start-ups, and the emphasis on ‘ease of doing business’ will benefit MSMEs. The government’s focus on research and innovation, especially agritech and industrial research, is a welcome move. The allocation of Rs 1 lakh crore financial pool will spur private sector-driven research and innovation at commercial scale. We will need to read the details to see how this will be allocated to each sector. The removal of Customs duty on three cancer drugs will provide relief to cancer patients. However, the government needs to consider GST exemption for all cancer drugs to make cancer care more affordable for patients.” -Kiran Mazumdar Shaw, Chairperson, Biocon & Biocon Biologics
-
Biocon reposted this
-
#Biocon takes great pride in unveiling its Integrated #AnnualReport for #FY2024. This year's theme -- ‘The Multiplier Effect: Maximizing Value' -- captures the compelling story of how the Biocon Group is leveraging its unique and differentiated strengths to multiply its positive impact on global #health even as it maximizes value for all stakeholders. The report presents a holistic overview of our performance over the last financial year both from a financial and non-financial perspective. You can access the Integrated Annual Report FY 2024 at bit.ly/BioconIAR2024. Happy Reading!
-
Understanding the dynamics of parents is crucial. It allows parents to better support their children's development, foster healthy relationships and create a nurturing environment. Dr Prasanth Gowda – Consultant, Paediatrician and Neonatologist took #Bioconites through a session on Neo-parenting and the influence of father's in early childhood development. At #Biocon, we believe in our commitment to supporting employees in every walk of life, from career growth to family dynamics. Let us empower each other and become the best version of parents and colleagues we can be.
-
Generics offer an equally safe and effective option as their branded counterparts as well as substantial savings. Discover #Biocon’s comprehensive range of high-quality #generics across various therapeutic areas. Visit this page to know more:
Generics - delivering quality products to patients, partners & healthcare
biocon.com
-
#Bioconites recently participated in an awareness session with Dr Ravi Kiran S K – Hepatology & Liver transplantation, on ‘Hepatitis’. The session delving into a variety of topics like Hepatitis and its types, causes, symptoms, treatment and many more. #HepatitisAwareness #LiverHealth